Mitochondrial and Energy Substrate Probes

1 Coenzyme Q10, NADH, D-Ribose, L-Carnitine, Alpha-Lipoic Acid

These supplements probe whether energy production failure is a rate-limiting contributor to symptoms. They supply substrates or cofactors to the electron transport chain, bypassing damaged complexes or augmenting residual capacity. Mitochondrial dysfunction is well-documented in ME/CFS; the diagnostic question is “which step is the bottleneck and how much can supplementation compensate?”

1.1 If mitochondrial supplements work

Finding: Energy production capacity was limiting function.

Supplement provided rate-limiting substrate → ATP production increased → symptoms improved.

Certainty: Low to Medium — CoQ10 meta-analysis (Tsai 2022) significant; NADH RCT (Forsyth 1999) 31% vs. 8% placebo. But trials are small, single-study, and effect sizes modest (10–30%).
Does NOT tell us: why the bottleneck exists (genetic, oxidative damage, safe mode downregulation).
Action: continuing supplementation + reducing demand through pacing + investigating the cause of mitochondrial impairment.
Level of action: Partial root cause — supplements augment impaired complexes without repairing them.

Finding: Specific bottleneck identifiable by differential response.

CoQ10 works but NADH doesn’t → bottleneck downstream of Complex I. NADH works but CoQ10 doesn’t → Complex I electron supply limiting. L-Carnitine works → fatty acid oxidation is the bottleneck. D-Ribose works → pentose phosphate pathway/purine salvage limiting ATP regeneration.

Certainty: Low — no direct comparative ME/CFS studies.
Level of action: Partial root cause.

Finding: Metabolic safe mode may be partially overridden.

If the safe mode has deliberately downregulated energy production (Metabolic “Safe Mode” Hypothesis), substrate supplementation may bypass regulated steps — but at the risk of working against the body’s protective program.

Certainty: Low — safe mode is a hypothesis.
Does NOT tell us: whether overriding safe mode is beneficial or harmful (may accelerate oxidative damage).
Level of action

1.2 What a positive response does NOT reveal

A positive response confirms that energy production capacity was limiting function but does not reveal why the bottleneck exists (genetic defect, oxidative damage, or deliberate safe-mode downregulation remain indistinguishable). Without a differential trial across the individual supplements, it does not localize which step is rate-limiting. It also cannot say whether bypassing a regulated safe-mode step is beneficial or harmful. Because the trials are small, single-study, and modest in effect size, a genuine effect cannot be cleanly separated from placebo.

1.3 If mitochondrial supplements do NOT work

Energy production not the rate-limiting symptom driver — ATP produced but cannot be used (neuroinflammation, receptor dysfunction, hypoperfusion).
Mitochondrial damage too severe for substrate bypass — complexes structurally damaged.
Safe mode actively suppressing energy production — regulatory program overrides substrate availability (itaconate shunt diverts TCA cycle intermediates).
Wrong substrate supplemented for the specific deficit.

1.4 Key caveat

Non-response does not exclude mitochondrial dysfunction. A safe-mode program actively suppressing energy production, or structurally damaged complexes that substrate cannot bypass, can leave the mechanism present while supplementation fails. Non-response may also reflect the wrong substrate for the specific bottleneck. Non-response is weaker evidence than response.

1.5 How Mitochondrial Supplements combine with other medications

Supplements + LDN both work → energy deficit + neuroinflammation (linked — inflammation impairs mitochondria).
Supplements + pyridostigmine both work → improved energy production + improved energy delivery (synergy).
Supplements do not work + LDA works → cognitive deficit is neurotransmitter-level, not energy-supply-level.

1.6 Compendium

The full pharmacodiagnostic entries — including mechanism-exclusion logic, dose-specific side-effect diagnostic patterns, combination diagnostics, and worsening risk profiles — are at Mechanistic Cascade Tracing: From Hypothesis to Clinical Probe (sec-12, individual mitochondrial cofactor entries: Coenzyme Q10, NADH, D-Ribose, L-Carnitine, Alpha-Lipoic Acid, and Mitochondrial Supplements group entry).

2 Creatine

Creatine probes the phosphocreatine ATP buffer — a battery backup that regenerates ATP faster than oxidative phosphorylation during bursts of cognitive or physical demand. It does not increase ATP production; it buffers supply against transient spikes in demand.

2.1 If creatine works

Finding: Brain ATP demand transiently exceeds production

Improvement means ATP demand periodically outstrips mitochondrial output, and the phosphocreatine buffer bridges the gap. This is consistent with the Architecture C metabolic reserve model (Architectural Uncertainty: Architecture A Cannot Be Ruled Out), in which baseline production is adequate but burst capacity is limited.

Certainty: Medium for cognition in healthy or sleep-deprived subjects; no ME/CFS-specific data.
Does NOT tell us: whether the underlying limit is reduced production capacity or elevated demand.
Action: Supports buffering the energy reserve; relevant for demand-driven cognitive dips.
Level of action: Symptom management — buffers ATP without increasing production.

2.2 What a positive response does NOT reveal

Whether the shortfall reflects a production deficit or a demand surge.
Whether mitochondrial function itself is impaired.

2.3 If creatine does NOT work

The cognitive deficit may arise from neurotransmitter insufficiency (e.g., dopaminergic), not an ATP gap.
Mitochondrial failure may be too severe for a buffer to compensate.
Creatine brain penetration may be insufficient in some individuals.

2.4 Key caveat

Creatine may raise serum creatinine and confound kidney-function tests; clinicians should interpret creatinine accordingly. Cycling may be preferable to continuous use.

2.5 How creatine combines with other medications

Creatine + mitochondrial supplements both work → both energy production and buffering are impaired.
Creatine works + mitochondrial supplements do not → production capacity is adequate but burst capacity is limited (a buffer deficit).
Creatine works + low-dose aripiprazole (LDA) does not → the cognitive deficit is energy-level, not neurotransmitter-level.

2.6 Compendium

The full pharmacodiagnostic entry — including mechanism-exclusion logic, dose-specific side-effect diagnostic patterns, combination diagnostics, and worsening risk profiles — is at Mechanistic Cascade Tracing: From Hypothesis to Clinical Probe (sec-12, Creatine entry).